Clearmind's Intranasal MEAI Formulation Shows Promising Permeation Results — Clearmind Medicine Inc.

Event summary

Clearmind Medicine reported positive permeation study results for its intranasal MEAI formulation on August 11, 2026.
The study confirmed enhanced nasal retention without compromising drug delivery efficiency.
Both the intranasal formulation and conventional solution achieved near-complete permeation (97.35% vs. 98.34%) within 180 minutes.
The findings support Clearmind's development strategy for treating alcohol use disorder (AUD) and weight management conditions.

The big picture

Clearmind's positive permeation results reinforce the potential of intranasal MEAI as a non-hallucinogenic therapeutic for under-treated conditions like AUD and obesity. The findings align with broader industry trends toward innovative drug delivery systems that enhance patient compliance and efficacy. Success in this area could position Clearmind as a key player in the neuroplastogen therapeutics space, particularly if it can sustain its development momentum through clinical trials.

What we're watching

Clinical Development Pace: How quickly Clearmind advances its intranasal MEAI program into later-stage clinical trials.
Market Differentiation: Whether the enhanced nasal retention and permeation data will position MEAI as a differentiated therapeutic option for AUD and metabolic disorders.
Regulatory Pathway: The timeline for securing regulatory approvals given the novel drug delivery mechanism.